PPI use linked to worse outcomes in urothelial cancer patients treated with atezolizu

[News]

Proton pump inhibitor (PPI) use was associated with worse outcomes in patients with urothelial cancer treated with the immunotherapeutic atezolizumab (Tecentriq), compared with patients who did not use PPIs.

More... (https://www.news-medical.net/news/20200917/PPI-use-linked-to-worse-outcomes-in-urothelial-cancer-patients-treated-with-atezolizumab.aspx)